EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis

Hilde Jenssen Bjørkekjær iD, Cosimo Bruni iD, Kaspar Broch iD, Cathrine Brunborg iD, Patricia E Carreira iD, Paolo Airò, Carmen Pilar Simeón-Aznar iD, Marie-Elise Truchetet iD, Alessandro Giollo iD, Alexandra Balbir-Gurman iD, Mickael Martin iD, Christopher P Denton iD und 19 weitere

Arthritis & Rheumatology · 11.11.2026

DOI: 10.1002/art.70372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 11.11.2026. Verfasst von Hilde Jenssen Bjørkekjær und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Real‐world initial treatment strategies in systemic sclerosis–associated pulmonary arterial hypertension (SSc‐PAH) remain incompletely described. We aimed to characterize these strategies across hemodynamic thresholds and risk strata and evaluate outcome associations.

Methods

We analyzed treatment‐naive patients with SSc‐PAH from the European Scleroderma Trials and Research (EUSTAR) database (2000–2021) who fulfilled the 2022 hemodynamic definition. Initial therapy comprised treatment initiated within four months of right heart catheterization. As‐treated (AT) analyses were primary and intention‐to‐treat (ITT) analyses supportive. Outcomes were all‐cause mortality and 36‐month PAH progression.

Results

Among 301 patients, 198 (66%) initiated therapy and 170 maintained therapy for at least three months. Therapy was initiated in 31% with milder hemodynamic impairment (mean pulmonary arterial pressure 21–24 mm Hg and/or pulmonary vascular resistance 2–3 Wood units) versus 79% fulfilling the previous hemodynamic definition; combination therapy increased from 14% to 67% across low‐ to high‐risk strata. Over a median 3.9 years, 125 patients (42%) died and 85 of 227 (37%) progressed. Adjusted ITT analyses showed no association with either outcome, whereas adjusted AT analyses showed lower mortality risk with sustained monotherapy and combination therapy (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.27–0.92, and HR 0.40, 95% CI 0.18–0.88, respectively) and lower PAH progression risk with sustained initial therapy (HR 0.37, 95% CI 0.18–0.76). In the milder hemodynamic subgroup, the mortality estimate was directionally consistent but imprecise.

Conclusion

Initial treatment strategies reflected hemodynamic severity and baseline risk, whereas variation suggested potential implementation gaps. Sustained initial therapy was associated with lower risks of mortality and PAH progression. Contrasting ITT and AT estimates highlight challenges in observational treatment–outcome comparisons. Findings in the milder hemodynamic subgroup support dedicated prospective studies. image

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Institute for Experimental Medical Research, KG Jebsen Center, University of Oslo, Oslo, Norway.
  • Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

ORCID-Profile: Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Carmen Pilar Simeón-Aznar, Marie-Elise Truchetet, Alessandro Giollo, Alexandra Balbir-Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C Vonk, Håvard Fretheim, Helle Bitter, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller-Ladner, Marco Matucci-Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna-Maria Hoffmann-Vold

Förderung

  • Janssen Research and Development

Zitieren

APA

Bjørkekjær, H. J., Bruni, C., Broch, K., Brunborg, C., Carreira, P. E., Airò, P., Simeón-Aznar, C. P., Truchetet, M. E., Giollo, A., Balbir-Gurman, A., Martin, M., Denton, C. P., Gabrielli, A., Del Galdo, F., Vonk, M. C., Fretheim, H., Bitter, H., Midtvedt, Ø., Andreassen, A. K., …, & European Scleroderma Trials and Research (EUSTAR) collaborators (2026). Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70372

Vancouver

Bjørkekjær HJ, Bruni C, Broch K, Brunborg C, Carreira PE, Airò P, et al. Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70372

BibTeX
@article{Bjrkekjr2026,
  author = {Bjørkekjær, Hilde Jenssen and Bruni, Cosimo and Broch, Kaspar and Brunborg, Cathrine and Carreira, Patricia E and Airò, Paolo and Simeón-Aznar, Carmen Pilar and Truchetet, Marie-Elise and Giollo, Alessandro and Balbir-Gurman, Alexandra and Martin, Mickael and Denton, Christopher P and Gabrielli, Armando and Del Galdo, Francesco and Vonk, Madelon C and Fretheim, Håvard and Bitter, Helle and Midtvedt, Øyvind and Andreassen, Arne K and Høie, Sverre and Tanaka, Yoshiya and Riemekasten, Gabriela and Müller-Ladner, Ulf and Matucci-Cerinic, Marco and Castellví, Ivan and Siegert, Elise and Hachulla, Eric and Molberg, Øyvind and Distler, Oliver and Hoffmann-Vold, Anna-Maria and European Scleroderma Trials and Research (EUSTAR) collaborators, European Scleroderma Trials and Research (EUSTAR) collaborators},
  title = {Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70372}
}
Kostenlos starten →